Cargando…
The Role of Wilms’ Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia
The Minimal Residual Disease(MRD) monitoring in acute myeloid leukemia (AML) is crucial to guide treatment after morphologic complete remission, to define the need for consolidation with allogeneic stem cell transplantation (Allo-SCT), and to detect impending relapse allowing early intervention. How...
Autores principales: | Lazzarotto, Davide, Candoni, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225390/ https://www.ncbi.nlm.nih.gov/pubmed/35743376 http://dx.doi.org/10.3390/jcm11123306 |
Ejemplares similares
-
Wilms Tumor-1 (WT1) rs16754 Polymorphism and Clinical Outcome in Acute Myeloid Leukemia
por: Ramzi, Mani, et al.
Publicado: (2019) -
Studies of Wilms’ Tumor (WT1) Gene Expression in Adult Acute Leukemias in Singapore
por: Lim, Che Kang, et al.
Publicado: (2007) -
The Wilms Tumor-1 (WT1) rs16754 polymorphism is a prognostic factor in acute myeloid leukemia (AML): a meta-analysis
por: Long, Jianting, et al.
Publicado: (2016) -
The Wilms’ tumor (WT1) gene: Methods and protocols
por: Agrawal, Suraksha
Publicado: (2018) -
Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 Marker
por: Alizad Ghandforoush, Nasrin, et al.
Publicado: (2016)